Fully Humanized Anti-TLR2 Antibodies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibodies targeting Toll-like Receptor 2 (TLR2) often induce human anti-mouse antibody (HAMA) responses, leading to reduced therapeutic efficacy due to their rodent origin, and existing humanization techniques like chimerism and CDR grafting may impair binding affinity and immunogenicity.
Innovation Solution
Development of fully humanized monoclonal antibodies with specific amino acid sequences for the light and heavy chains that are entirely of human origin, devoid of murine residues, capable of binding to human TLR2 and neutralizing its activity without requiring CD32 binding, thus minimizing immunogenicity and maintaining high affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rodent monoclonal antibodies are used to target TLR2, then binding specificity and therapeutic effect are achieved, but human anti-mouse antibody (HAMA) responses are induced leading to reduced therapeutic efficacy
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence composition of the antibody to transition from rodent origin to fully human origin. This involves changing the fundamental parameter of species origin while maintaining the functional parameter of TLR2 binding capability, thereby eliminating HAMA responses while preserving therapeutic efficacy.
Solution Approach 2:
The patent creates a humanized version of the rodent antibody by copying the essential binding characteristics and structural features of the original rodent antibody while replacing the amino acid sequences with human-derived sequences. This allows the antibody to maintain its therapeutic function while being immunologically compatible with humans.
2Object-affected harmful factors
If chimerism or CDR grafting techniques are used to humanize antibodies, then immunogenicity is reduced, but binding affinity and therapeutic effectiveness are impaired
Solution Approach 1:
The patent achieves a superior balance by changing the parameter of amino acid sequence composition to use fully human sequences rather than partial humanization. This complete transformation maintains high binding affinity while maximizing reduction of immunogenicity, overcoming the limitations of incremental humanization approaches.
Solution Approach 2:
Instead of starting with a rodent antibody and partially humanizing it (the conventional approach), the patent inverts the approach by developing de novo fully human antibodies that naturally possess both high human compatibility and high binding affinity, avoiding the inherent trade-offs of partial humanization techniques.
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
A fully humanised antibody having binding specificity to Toll-like Receptor 2 comprising a light chain and a heavy chain entirely comprised of amino acid sequence of human origin. The variable region of the light chain comprises an amino acid sequence which is substantially homologous with the sequence of 5 SEQ ID NO:1, while the variable region of the heavy domain comprises an amino acid sequence which is substantially homologous with the sequence of SEQ ID NO:4. Also provided are nucleic acids encoding such antibodies, as well as the use of the antibodies in medicine, in particular for the treatment of inflammatory and autoimmune diseases which are mediated by Toll-like Receptor 2 activation 10 and signalling.